PA8621201A1 - Composicion farmaceutica apta la comprension directa para la administracion oral de cci-779 - Google Patents
Composicion farmaceutica apta la comprension directa para la administracion oral de cci-779Info
- Publication number
- PA8621201A1 PA8621201A1 PA20058621201A PA8621201A PA8621201A1 PA 8621201 A1 PA8621201 A1 PA 8621201A1 PA 20058621201 A PA20058621201 A PA 20058621201A PA 8621201 A PA8621201 A PA 8621201A PA 8621201 A1 PA8621201 A1 PA 8621201A1
- Authority
- PA
- Panama
- Prior art keywords
- cci
- approves
- pharmaceutical composition
- oral administration
- direct understanding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
SE DESCRIBE CCI-779 MICRONIZADO. ESTE 42-ESTER DE RAPAMICINA CON ACIDO 3-HIDROXI-2-(HIDROXIMETIL)-2-METILPROPIONICO APTO PARA LA COMPRESION DIRECTA OFRECE UN METODO CONVENIENTE Y EFICAZ PARA ADMINISTRAR NIVELES TERAPEUTICOS DE CCI-779 A UN PACIENTE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53495104P | 2004-01-08 | 2004-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8621201A1 true PA8621201A1 (es) | 2005-12-23 |
Family
ID=34806893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20058621201A PA8621201A1 (es) | 2004-01-08 | 2005-01-07 | Composicion farmaceutica apta la comprension directa para la administracion oral de cci-779 |
Country Status (31)
Country | Link |
---|---|
US (1) | US20050152983A1 (es) |
EP (1) | EP1701698B1 (es) |
JP (1) | JP2007517879A (es) |
KR (1) | KR20060130162A (es) |
CN (1) | CN1921861A (es) |
AR (1) | AR047180A1 (es) |
AT (1) | ATE383859T1 (es) |
AU (1) | AU2004314213A1 (es) |
BR (1) | BRPI0418373A (es) |
CA (1) | CA2552595A1 (es) |
CR (1) | CR8491A (es) |
CY (1) | CY1107373T1 (es) |
DE (1) | DE602004011398T2 (es) |
DK (1) | DK1701698T3 (es) |
EC (1) | ECSP066757A (es) |
ES (1) | ES2298861T3 (es) |
GT (1) | GT200500003A (es) |
HK (1) | HK1090308A1 (es) |
HN (1) | HN2005000005A (es) |
IL (1) | IL176519A0 (es) |
MX (1) | MXPA06007829A (es) |
NO (1) | NO20062930L (es) |
PA (1) | PA8621201A1 (es) |
PE (1) | PE20050683A1 (es) |
PL (1) | PL1701698T3 (es) |
PT (1) | PT1701698E (es) |
RU (1) | RU2006122517A (es) |
TW (1) | TW200526213A (es) |
UA (1) | UA84903C2 (es) |
WO (1) | WO2005070393A2 (es) |
ZA (1) | ZA200605631B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
CA2562952A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
MXPA06012404A (es) * | 2004-04-27 | 2007-01-17 | Wyeth Corp | Marcado de rapamicina usando metilasas especificas de rapamicina. |
EP1855656A2 (en) * | 2005-02-15 | 2007-11-21 | Wyeth | Orally bioavailable cci-779 tablet formulations |
EP1962839A4 (en) | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
US9364502B2 (en) * | 2006-06-28 | 2016-06-14 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
CN110354132A (zh) | 2012-06-04 | 2019-10-22 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
TW202315634A (zh) | 2015-03-03 | 2023-04-16 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
EP3345601A4 (en) * | 2015-09-03 | 2019-05-15 | Nippon Kayaku Kabushiki Kaisha | PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF |
WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5928668A (en) * | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
KR100542816B1 (ko) * | 1996-08-22 | 2006-01-11 | 알티피 파마 코포레이션 | 수불용성 물질의 미립자를 포함하는 조성물 및 이것의 제조 방법 |
US5989591A (en) * | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
DK1635830T3 (da) * | 2002-09-17 | 2009-02-23 | Wyeth Corp | Granulatformulering af rapamycinesteren CCI-779 |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
SG144165A1 (en) * | 2003-07-25 | 2008-07-29 | Wyeth Corp | Cci-779 lyophilized formulations |
MXPA06000951A (es) * | 2003-08-07 | 2006-03-30 | Wyeth Corp | Sintesis regioselectiva de cci-779. |
EP1660081A1 (en) * | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
US20060142422A1 (en) * | 2004-12-07 | 2006-06-29 | Toshikazu Kobayashi | Hydrolysis resistant polyester compositions and articles made therefrom |
EP1855656A2 (en) * | 2005-02-15 | 2007-11-21 | Wyeth | Orally bioavailable cci-779 tablet formulations |
-
2004
- 2004-12-14 PT PT04814371T patent/PT1701698E/pt unknown
- 2004-12-14 DE DE602004011398T patent/DE602004011398T2/de active Active
- 2004-12-14 PL PL04814371T patent/PL1701698T3/pl unknown
- 2004-12-14 MX MXPA06007829A patent/MXPA06007829A/es active IP Right Grant
- 2004-12-14 RU RU2006122517/15A patent/RU2006122517A/ru not_active Application Discontinuation
- 2004-12-14 AU AU2004314213A patent/AU2004314213A1/en not_active Abandoned
- 2004-12-14 CA CA002552595A patent/CA2552595A1/en not_active Abandoned
- 2004-12-14 CN CNA2004800399872A patent/CN1921861A/zh active Pending
- 2004-12-14 ES ES04814371T patent/ES2298861T3/es active Active
- 2004-12-14 AT AT04814371T patent/ATE383859T1/de not_active IP Right Cessation
- 2004-12-14 DK DK04814371T patent/DK1701698T3/da active
- 2004-12-14 WO PCT/US2004/042178 patent/WO2005070393A2/en active IP Right Grant
- 2004-12-14 UA UAA200608870A patent/UA84903C2/ru unknown
- 2004-12-14 EP EP04814371A patent/EP1701698B1/en active Active
- 2004-12-14 JP JP2006549291A patent/JP2007517879A/ja not_active Withdrawn
- 2004-12-14 KR KR1020067015655A patent/KR20060130162A/ko not_active Application Discontinuation
- 2004-12-14 BR BRPI0418373-8A patent/BRPI0418373A/pt not_active IP Right Cessation
- 2004-12-27 TW TW093140750A patent/TW200526213A/zh unknown
-
2005
- 2005-01-04 AR ARP050100016A patent/AR047180A1/es not_active Application Discontinuation
- 2005-01-05 GT GT200500003A patent/GT200500003A/es unknown
- 2005-01-06 US US11/030,685 patent/US20050152983A1/en not_active Abandoned
- 2005-01-06 HN HN2005000005A patent/HN2005000005A/es unknown
- 2005-01-06 PE PE2005000043A patent/PE20050683A1/es not_active Application Discontinuation
- 2005-01-07 PA PA20058621201A patent/PA8621201A1/es unknown
-
2006
- 2006-06-22 IL IL176519A patent/IL176519A0/en unknown
- 2006-06-22 NO NO20062930A patent/NO20062930L/no not_active Application Discontinuation
- 2006-06-28 CR CR8491A patent/CR8491A/es not_active Application Discontinuation
- 2006-07-07 ZA ZA200605631A patent/ZA200605631B/xx unknown
- 2006-08-08 EC EC2006006757A patent/ECSP066757A/es unknown
- 2006-11-07 HK HK06112221A patent/HK1090308A1/xx not_active IP Right Cessation
-
2008
- 2008-03-31 CY CY20081100359T patent/CY1107373T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP066757A (es) | 2006-11-16 |
WO2005070393A3 (en) | 2006-09-28 |
GT200500003A (es) | 2005-08-18 |
WO2005070393A2 (en) | 2005-08-04 |
DK1701698T3 (da) | 2008-05-05 |
EP1701698B1 (en) | 2008-01-16 |
PT1701698E (pt) | 2008-03-27 |
MXPA06007829A (es) | 2006-09-01 |
CR8491A (es) | 2008-08-21 |
ZA200605631B (en) | 2010-01-27 |
EP1701698A2 (en) | 2006-09-20 |
US20050152983A1 (en) | 2005-07-14 |
HK1090308A1 (en) | 2006-12-22 |
BRPI0418373A (pt) | 2007-05-22 |
CA2552595A1 (en) | 2005-08-04 |
CN1921861A (zh) | 2007-02-28 |
RU2006122517A (ru) | 2008-02-20 |
JP2007517879A (ja) | 2007-07-05 |
UA84903C2 (ru) | 2008-12-10 |
PE20050683A1 (es) | 2005-11-04 |
TW200526213A (en) | 2005-08-16 |
ATE383859T1 (de) | 2008-02-15 |
HN2005000005A (es) | 2009-04-17 |
PL1701698T3 (pl) | 2008-03-31 |
NO20062930L (no) | 2006-10-02 |
IL176519A0 (en) | 2006-10-05 |
DE602004011398D1 (de) | 2008-03-06 |
AU2004314213A1 (en) | 2005-08-04 |
KR20060130162A (ko) | 2006-12-18 |
DE602004011398T2 (de) | 2009-01-15 |
AR047180A1 (es) | 2006-01-11 |
CY1107373T1 (el) | 2012-12-19 |
ES2298861T3 (es) | 2008-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8621201A1 (es) | Composicion farmaceutica apta la comprension directa para la administracion oral de cci-779 | |
EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
NO20065227L (no) | Menoklonale antistoff mot hepatocytt vekstfaktor | |
SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
RU2011141123A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ | |
SE0401342D0 (sv) | Therapeutic compounds | |
CY1110133T1 (el) | Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ | |
ECSP067095A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
EA200501819A1 (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
TW200612909A (en) | Compounds | |
EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
EA201171043A1 (ru) | Композиции и способы длительной терапии с применением аминопиридинов | |
WO2012020412A3 (en) | Fibrin based scaffold, preparation and use thereof | |
WO2008137780A3 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
BRPI0518619A2 (pt) | mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica | |
DK1030667T3 (da) | Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö | |
DE60107399D1 (de) | Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin | |
RU2012130932A (ru) | Антикоагулянтные соединения и их применение | |
SV2006001989A (es) | Composicion farmaceutica apta para la compresion directa para la administracion oral de cci - 779 ref. am-101453salvo | |
EA200601514A1 (ru) | Производные пиперазинмочевины для лечения эндометриоза |